ArticleBiogerontology2026
DHCR24 regulates endothelial senescence through the SPHK2/SPNS2-S1P axis.
Article in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Vascular endothelial senescence is a pivotal driver of age-related pathologies. Metabolism plays a critical regulatory role in endothelial cell senescence. Our previous studies have shown that deficiency of DHCR24, a gene involved in lipid metabolism, promotes endothelial cell senescence. However, how DHCR24 participates in endothelial cell senescence through lipid metabolism remains unclear. Using endothelial-specific DHCR24 knockout mice and replicative senescent human umbilical vein endothelial cells, we demonstrate that DHCR24 depletion significantly reduced intracellular sphingosine-1-phosphate (S1P) levels. Mechanistically, DHCR24 loss downregulated sphingosine kinase 2 (SPHK2), impairing S1P synthesis, while concurrently upregulating the S1P transporter (SPNS2), enhancing S1P export. Critically, SPHK2 overexpression rescued senescence phenotypes in DHCR24-deficient cells. SPHK2 knockdown recapitulated SPNS2 upregulation and endothelial senescence, whereas pharmacological inhibition of SPNS2 with 16d attenuated SPHK2 knockdown-induced increases in p16, p21 and SA-β-gal activity, and restored eNOS expression and nitric oxide (NO) production. In vivo, endothelial-specific DHCR24 knockout increased circulating S1P levels, and plasma S1P was positively correlated with pulse wave velocity in humans. Collectively, these findings suggest the DHCR24-SPHK2/SPNS2-S1P axis as an important pathway involved in endothelial senescence.
Indexed as
Identifiers
42704384What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.